Abolere mortem

What actually changed in longevity science

Research worth understanding. News worth reading. A clearer view of living longer.

Longevity landscape

85.7years

Modeled age at death · +2.3 vs reference

Research comparison across study populations—not a personal forecast.

Click a line to see the exact studies that calculate it. Use the tags in the feed to add or remove evidence.

4 selected source groups · 50% effect transfer. Sources include different study populations; their combined effect has not been tested as a treatment package.

Starting ageUS life table

Model assumptions

Include observational evidenceReported benefit carried into modelAdditional overlapping benefitsAssumed effect duration

Effect transfer and overlap are sensitivity assumptions, not measured correction factors. Age and sex change the reference life table; they do not establish treatment eligibility. Shading shows source bounds, not a combined confidence interval.

Nonfatal harms, adherence and treatment interactions are not modeled. Model longevity-scenarios-1.

Methodology & limitations →

What matters now

Important findings, useful explanations, and setbacks worth knowing about.

All stories →

10 stories from the past 72 hours. Older stories keep their original dates. Ranking reflects relevance, recency and reader interest—not proof of benefit.

Longevity news

News, research and the studies that currently shape the longevity chart—all in one stream.

News coverage· The Guardian
On dementia, we need to tell it how it is | Letter
Published Oct 25, 2026Added 5hStart a discussion Share on X
The Guardian reports on this topic. Open the source for the full explanation.
Source coverage · not an evidence rating
Read the article · The Guardian ↗
News coverage· The Guardian
The joy of veg-maxxing: how to eat many, many more plants – without really trying
Published Oct 25, 2026Added 9hStart a discussion Share on X
The Guardian reports on this topic. Open the source for the full explanation.
Source coverage · not an evidence rating
Read the article · The Guardian ↗
News coverage· The Guardian
Ethnic minorities in England diagnosed with breast cancer less often through routine screening
Published Oct 25, 2026Added 9hStart a discussion Share on X
People from minority ethnic backgrounds in England are up to one-third less likely to receive a breast cancer diagnosis through routine screening and more likely to be diagnosed in emergency settings, based on analysis of 86,564 patients diagnosed between 2009 and 2019.
Why it matters: Screening disparities may delay diagnosis and worsen outcomes for minority ethnic groups.
AI-assisted explanation · Source coverage · not an evidence rating
Read the article · The Guardian ↗
Research affecting the chart· PubMed
Combined lifestyle factors, all-cause mortality and cardiovascular disease
Published 2020Observational researchGeneral adult evidence
Directly changes the Combined lifestyle chart input
74 studies; 2,584,766 participants in the all-cause mortality analysis.
Study scope and limits
Adults in prospective cohorts; populations and lifestyle definitions varied.
Healthiest versus least-healthy combinations of smoking, activity, diet, weight and alcohol factors.
Observational association, with residual confounding and heterogeneous lifestyle scores. Not the effect of changing an average person’s habits. Alcohol in the score is not a recommendation to drink.
Read the study · PubMed ↗
News coverage· BBC News
Wellbeing support demand for cancer patients grows
Published Oct 25, 2026Added 15hStart a discussion Share on X
BBC News reports on this topic. Open the source for the full explanation.
Source coverage · not an evidence rating
Read the article · BBC News ↗
News coverage· The Guardian
Britain's cocaine use shows aging users taking drug more frequently
Published Oct 25, 2026Added 15hStart a discussion Share on X
Cocaine-related deaths in Britain have reached record levels, with data showing established users consuming the drug more often rather than millions of new users entering the market. Aging users face greater harm as consumption patterns intensify.
Why it matters: Understanding shifting cocaine use patterns helps public health officials target interventions toward aging users experiencing greater drug-related harm.
AI-assisted explanation · Source coverage · not an evidence rating
Read the article · The Guardian ↗
Research affecting the chart· PubMed
Associations Between Exercise Training, Physical Activity, Sedentary Behaviour and Mortality
Published 2025Observational researchGeneral adult evidence
Directly changes the Physical activity chart input
Umbrella review of meta-analyses; equivalent hazard ratio for leisure-time physical activity.
Study scope and limits
Adults in the self-reported leisure-time physical activity syntheses.
Higher versus lower self-reported leisure-time physical activity; contrasts vary across studies.
Authors classify the association as suggestive evidence. Self-report, residual confounding and overlapping reviews limit interpretation. Replaces the combined lifestyle estimate rather than stacking on it.
Read the study · PubMed ↗
News coverage· BBC News
Obsessive fitness pursuit can trigger anxiety and sleep loss
Published Oct 23, 2026Added 2dStart a discussion Share on X
A runner's excessive focus on race times and social media comparison caused constant worry, anxiety, and sleep deprivation. This describes one person's experience with compulsive exercise behavior.
Why it matters: Exercise addiction can harm mental health and sleep, not just physical health.
AI-assisted explanation · Source coverage · not an evidence rating
Read the article · BBC News ↗
News coverage· The Guardian
Weight-loss drugs may reduce alcohol consumption, brewer warns
Published Oct 23, 2026Added 2dStart a discussion Share on X
Heineken warned UK pubs that GLP-1 weight-loss medications like Wegovy and Ozempic could reduce people's desire to drink alcohol, potentially lowering beer and cider sales.
Why it matters: This signals potential economic impacts on the hospitality industry if weight-loss drug use becomes widespread.
AI-assisted explanation · Source coverage · not an evidence rating
Read the article · The Guardian ↗
Research affecting the chart· PubMed
Efficacy and safety of more intensive lowering of LDL cholesterol
Published 2010Randomized researchCardiovascular prevention trial populations
Directly changes the Statins chart input
CTT individual participant meta-analysis of 26 trials; about 170,000 participants overall.
Study scope and limits
Participants enrolled in randomized LDL-lowering trials, with varied cardiovascular risk.
Per 1 mmol/L lower LDL cholesterol, across statin versus control and more- versus less-intensive regimens.
Mortality rate ratio is treated as a proportional hazard multiplier in this model. Trial populations and LDL changes differ; not a longevity estimate for healthy people or a prescribing recommendation.
Read the study · PubMed ↗
News coverage· BBC News
First personalised cancer vaccine cuts risk of disease returning in major trial
Published Oct 23, 2026Added 2dStart a discussion Share on X
BBC News reports on this topic. Open the source for the full explanation.
Source coverage · not an evidence rating
Read the article · BBC News ↗
News coverage· The Guardian
Indian court backs price caps on cancer drugs following affordability case
Published Oct 23, 2026Added 2dStart a discussion Share on X
India's government will reduce prices of 137 cancer drugs after a court case highlighted how high costs force patients to forgo treatment, sell land, or go into debt.
Why it matters: Drug affordability directly affects whether people can access cancer treatment and avoid financial ruin.
AI-assisted explanation · Source coverage · not an evidence rating
Read the article · The Guardian ↗
Research affecting the chart· PubMed
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting GLP-1 Receptor Agonists
Published 2025Randomized researchType 2 diabetes trial populations
Directly changes the GLP-1 agonists chart input
10 randomized trials; 71,351 participants.
Study scope and limits
People with type 2 diabetes in large cardiovascular and kidney outcome trials.
Long-acting GLP-1 receptor agonist versus placebo, on top of trial background care.
Class-level synthesis in type 2 diabetes; not transferable to healthy adults, every agent, or lifelong use. Trials already include other care, so combining effects can double-count benefit.
Read the study · PubMed ↗
News coverage· BBC News
Breast cancer survivor reflects on overcoming childhood fear
Published Oct 23, 2026Added 2dStart a discussion Share on X
Harriet Tsadioti, a breast cancer survivor, discusses how the disease was a major concern for her during childhood. She shares her personal experience with the condition.
Why it matters: Personal narratives about cancer can help others understand the disease's impact.
AI-assisted explanation · Source coverage · not an evidence rating
Read the article · BBC News ↗
Research affecting the chart· journals.plos.org
SGLT2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes
Published 2023Randomized researchChronic kidney disease trial populations
Directly changes the SGLT2 inhibitors chart input
Systematic review of 14 randomized trials; all-cause mortality is a secondary endpoint.
Study scope and limits
People with chronic kidney disease, with or without type 2 diabetes.
SGLT2 inhibitor plus standard therapy versus placebo or standard therapy.
The 14 trials cover the review as a whole, not necessarily this endpoint. Kidney disease populations differ from the reference life table. Background treatment overlaps with other selections.
Read the study · journals.plos.org ↗

Find topics to follow

Explore a topic, read its evidence, and follow future updates.

Epigenetic clocks →Metformin →Senolytics →Smoking cessation →Exercise →SGLT2 inhibitors →Klotho →Air quality →